Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

(S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.

Morishita K, Miike T, Takeda S, Fukui M, Ito Y, Kitao T, Ozawa SI, Hirono S, Shirahase H.

Chem Pharm Bull (Tokyo). 2019;67(11):1211-1224. doi: 10.1248/cpb.c19-00541.

2.

Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.

Otake K, Azukizawa S, Takeda S, Fukui M, Kawahara A, Kitao T, Shirahase H.

Chem Pharm Bull (Tokyo). 2015;63(12):998-1014. doi: 10.1248/cpb.c15-00508.

3.

2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation.

Morishita K, Shoji Y, Fukui M, Ito Y, Kitao T, Ozawa SI, Hirono S, Shirahase H.

Chem Pharm Bull (Tokyo). 2018;66(12):1131-1152. doi: 10.1248/cpb.c18-00571.

4.

A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity.

Otake K, Azukizawa S, Fukui M, Shibabayashi M, Kamemoto H, Miike T, Kunishiro K, Kasai M, Shirahase H.

Chem Pharm Bull (Tokyo). 2011;59(10):1233-42.

5.

Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.

Otake K, Azukizawa S, Fukui M, Kunishiro K, Kamemoto H, Kanda M, Miike T, Kasai M, Shirahase H.

Bioorg Med Chem. 2012 Jan 15;20(2):1060-75. doi: 10.1016/j.bmc.2011.11.035. Epub 2011 Dec 1.

PMID:
22197396
7.
8.

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.

Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8. Epub 2009 May 27.

PMID:
19471887
9.

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.

Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Märki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M.

Mol Endocrinol. 2006 Apr;20(4):809-30. Epub 2005 Dec 22.

PMID:
16373399
10.

Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.

Eeda V, Wu D, Lim HY, Wang W.

Bioorg Med Chem Lett. 2019 Nov 15;29(22):126664. doi: 10.1016/j.bmcl.2019.126664. Epub 2019 Sep 3.

PMID:
31591015
11.

Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.

Goto T, Nakayama R, Yamanaka M, Takata M, Takazawa T, Watanabe K, Maruta K, Nagata R, Nagamine J, Tsuchida A, Kato H.

Exp Clin Endocrinol Diabetes. 2015 Sep;123(8):492-9. doi: 10.1055/s-0035-1549965. Epub 2015 May 26.

PMID:
26011171
12.

Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.

Zhang X, Liu H, Sun B, Sun Y, Zhong W, Liu Y, Chen S, Ling H, Zhou L, Jing X, Qin Y, Xiao T, Sun T, Zhou H, Yang C.

Sci Rep. 2016 Nov 17;6:37323. doi: 10.1038/srep37323.

13.

Selective Inhibition of PTP1B by Vitalboside A from Syzygium cumini Enhances Insulin Sensitivity and Attenuates Lipid Accumulation Via Partial Agonism to PPARγ: In Vitro and In Silico Investigation.

Thiyagarajan G, Muthukumaran P, Sarath Kumar B, Muthusamy VS, Lakshmi BS.

Chem Biol Drug Des. 2016 Aug;88(2):302-12. doi: 10.1111/cbdd.12757. Epub 2016 Apr 6.

PMID:
26989847
14.

Honokiol: a non-adipogenic PPARγ agonist from nature.

Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, Fakhrudin N, Ladurner A, Malainer C, Vuorinen A, Noha SM, Schwaiger S, Rollinger JM, Schuster D, Stuppner H, Dirsch VM, Heiss EH.

Biochim Biophys Acta. 2013 Oct;1830(10):4813-9. doi: 10.1016/j.bbagen.2013.06.021. Epub 2013 Jun 27.

15.

Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.

Yamamoto A, Kakuta H, Sugimoto Y.

Int Immunopharmacol. 2014 Sep;22(1):204-8. doi: 10.1016/j.intimp.2014.06.028. Epub 2014 Jun 27.

PMID:
24975659
16.

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, Choi HH, Hur Y, Kim E, Park YH, Park CS, Kim JG, Lim JI, Shin CY.

Eur J Pharmacol. 2011 Jan 15;650(2-3):673-81. doi: 10.1016/j.ejphar.2010.10.044. Epub 2010 Oct 23.

PMID:
20974124
17.

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE.

Mol Endocrinol. 2003 Apr;17(4):662-76. Epub 2003 Jan 16.

PMID:
12554792
18.

Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice.

Ito Y, Fukui M, Kanda M, Morishita K, Shoji Y, Kitao T, Hinoi E, Shirahase H.

J Pharmacol Sci. 2018 May;137(1):38-46. doi: 10.1016/j.jphs.2018.03.001. Epub 2018 Mar 6.

19.

A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.

Bruemmer D, Berger JP, Liu J, Kintscher U, Wakino S, Fleck E, Moller DE, Law RE.

Eur J Pharmacol. 2003 Apr 18;466(3):225-34.

PMID:
12694805
20.

Potent Anti-Diabetic Actions of a Novel Non-Agonist PPARγ Ligand that Blocks Cdk5-Mediated Phosphorylation.

Kamenecka TM, Busby SA, Kumar N, Choi JH, Banks AS, Vidovic D, Cameron MD, Schurer SC, Mercer BA, Hodder P, Spiegelman BM, Griffin PR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Jul 5 [updated 2013 Mar 7].

Supplemental Content

Support Center